VISUAL OUTCOME IN DIABETIC MACULAR EDEMA AFTER GRID LASER TREATMENT

Similar documents
ROLE OF LASER PHOTOCOAGULATION VERSUS INTRAVITREAL TRIAMCINOLONE ACETONIDE IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETES MELLITUS

Clinically Significant Macular Edema (CSME)

Study of clinical significance of optical coherence tomography in diagnosis & management of diabetic macular edema

COMPARISON OF INTRAVITREAL TRIAMCINOLONE INJECTION VS LASER PHOTOCOAGULATION IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETIC RETINOPATHY

Clinical Trials in Diabetic Retinopathy. Harry W. Flynn Jr., M.D. Nidhi Relhan Batra, M.D.

Is OCT-A Needed As An Investigative Tool During The Management Of Diabetic Macular Edema

Andrew J. Barkmeier, MD; Benjamin P. Nicholson, MA; Levent Akduman, MD

Case Report Inherent Challenges in Managing Long Standing Refractory Diabetic Macular Edema

Fundus Fluorescein Angiography in Diabetic Retinopathy: Correlation of Angiographic Findings to the Clinical Maculopathy Abstract: Purpose:

EFFICACY OF INTRAVITREAL TRIAMCINOLONE ACETONIDE FOR THE TREATMENT OF DIABETIC MACULAR EDEMA

Diagnosis and treatment of diabetic retinopathy. Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City

THE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION

OCT Assessment of the Vitreoretinal Relationship in CSME

Recalcitrant Diabetic Macular Oedema: Therapeutic Options

International Journal of Health Sciences and Research ISSN:

PART 1: GENERAL RETINAL ANATOMY

A retrospective nonrandomized study was conducted at 3

Diabetic retinopathy (DR) progressively

Diabetic Retinopathy. Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012

optic disc neovascularisation

Extensive argon laser photocoagulation in the


The Diabetic Retinopathy Clinical Research Network. Management of DME in Eyes with PDR

Diabetic Management beyond traditional risk factors and LDL-C control: Can we improve macro and microvascular risks?

Diabetic Maculopathy in Nonproliferative Diabetic Retinopathy in Tertiary Eye Care Hospital in India: A Prospective Nonrandomized Clinical Study

JMSCR Vol 06 Issue 12 Page December 2018

Clinical Outcomes After Intravitreal Bevacizumab Injection for Diabetic Macular Edema

Vitrectomy for Diabetic Cystoid Macular Edema

Clinical Case Presentation. Branch Retinal Vein Occlusion. Sarita M. Registered Nurse Whangarei Base Hospital

The Human Eye. Cornea Iris. Pupil. Lens. Retina

New Developments in the treatment of Diabetic Retinopathy

Neuropathy (NAION) and Avastin. Clinical Assembly of the AOCOO-HNS Foundation May 9, 2013

Optical Coherence Tomograpic Features in Idiopathic Retinitis, Vasculitis, Aneurysms and Neuroretinitis (IRVAN)

Jay M. Haynie, O.D.; F.A.A.O. Olympia Tacoma Renton Kennewick Washington

Study of 189 Cases of Diabetic Retinopathy at CMC Larkana

SUMMARY. Heather Casparis, MD,* and Neil M. Bressler, MD MARINA AND ANCHOR

Diabetic Retinopathy WHAT IS DIABETIC RETINOPATHY? WHAT CAUSES DIABETIC RETINOPATHY? WHAT ARE THE STAGES OF DIABETIC RETINOPATHY?

Diabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches

Evaluation of Changes of Macular Thickness in Diabetic Retinopathy after Cataract Surgery

Scott M. Pfahler D.O. Dayton Vitreo-Retinal Associates AOCOO-HNS Palm Springs, CA 2012

biomicroscopy and stereoscopic photography are subjective and insensitive to small changes in retinal thickness ] 5[ Measurement of the integrity of t

Use of Scanning Laser Ophthalmoscope Microperimetry in Clinically Significant Macular Edema in Type 2 Diabetes Mellitus

A Patient s Guide to Diabetic Retinopathy

Optical coherence tomography in diabetic macular edema: patterns and related risk factors

Eyes on Diabetics: How to Avoid Blindness in Diabetic Patient

PERIMETRIC LONG-TERM FOLLOW-UP OF DIABETIC CYSTOID MACULAR EDEMA AFTER LASER TREATMENT EXTENDED TO THE FOVEAL AVASCULAR ZONE

Diabetic Retinopathy: Managing the Extremes. J. Michael Jumper, MD West Coast Retina

Diabetic Retinopathy

Diabetic Retinopathy A Presentation for the Public

Macular edema (ME) is the most common

Intravitreal versus Posterior Subtenon Injection of Triamcinolone Acetonide for Diabetic Macular Edema

FRANZCO, MD, MBBS. Royal Darwin Hospital

Treatment of Diabetic Macular Edema without Intravitreal injections

Preliminary report on effect of retinal panphotocoagulation on rubeosis iridis and

Prophylaxis of Macular edema with Peroperative Intravitreal Bevacizumab in Diabetic Retinopathy Patients Undergoing Phacoemulsification

Neovascular Glaucoma Associated with Cilioretinal Artery Occlusion Combined with Perfused Central Retinal Vein Occlusion

Thesis Submitted by. Moataz Hamed Mohamed. M.B.B.Ch, M.Sc. (Ophthalmology) In Partial Fulfillment of MD Degree in Ophthalmology Under Supervision of

Diabetic maculopathy 11/ An update on. Miss Vasuki Sivagnanavel

The beneficial effects of focal photocoagulation for clinically

Original Article. Authors

ZEISS AngioPlex OCT Angiography. Clinical Case Reports

Brampton Hurontario Street Brampton, ON L6Y 0P6

Role of OCT in the diagnosis and follow up of diabetic macular edema

Vascular Disease Ocular Manifestations of Systemic Hypertension

OCCLUSIVE VASCULAR DISORDERS OF THE RETINA

DIABETIC RETINOPATHY IS

Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial

Retina Conference. Janelle Fassbender, MD, PhD University of Louisville Department of Ophthalmology and Visual Sciences 09/04/2014

Original Article. Exudative Diabetic Maculopathy Treated By Frequancy Doubled Nd: Yag Laser (532nm)

Clinical Study Choroidal Thickness in Eyes with Unilateral Ocular Ischemic Syndrome

You can C-ME after Uveitis

Diabetic Retinopathy Clinical Research Network

Diabetes mellitus: A risk factor affecting visual outcome in branch retinal vein occlusion

INTRODUCTION. Trans Am Ophthalmol Soc 2010;108:62-76

Philadelphia College of Osteopathic Medicine. Heather Bladek Philadelphia College of Osteopathic Medicine,

Subclinical Diabetic Macular Edema Study

Intravitreal bevacizumab for pediatric exudative retinal diseases

Photocoagulation of disciform macular lesions

Recognising and managing diabetic retinopathy

Treatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity

Medical Retina 2011 Nicholas Lee

In its initial report, the Early Treatment Diabetic Retinopathy. A Severity Scale for Diabetic Macular Edema Developed from ETDRS Data

IQ 532 Micropulse Green Laser treatment for Refractory Chronic Central Serous Retinopathy

EU Regulatory workshop Ophthalmology clinical development and scientific advice. Industry view on DME and macular edema secondary to RVO

CENTRAL SEROUS CHORIORETINOPATHY (CSC) IS

Preparing for laser treatment for diabetic retinopathy and maculopathy

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal. Aflibercept for treating diabetic macular oedema.

Serious Eye diseases, New treatments. Mr. M. Usman Saeed MBBS, FRCS, FRCOphth Consultant Ophthalmologist

CSME BCVA. OCT Bevacizumab CMT CMT BCVA. BCVA LogMAR. p CMT NPDR PDR PDR. Bevacizumab PDR FDA. Ranibizumab. Bevacizumab.

The Era of anti- - - VEGF Kirk L. Halvorson, OD

Paradigm Shift in the treatment of Diabetic Retinopathy. Haytham I. S. Salti, MD Associate Professor

Retinal Complications of Obstructive Sleep Apnea A Growing Concern!

R&M Solutions

Vitrectomy Combined with Phacoemulsification and Intraocular Lens Implantation for Diabetic Macular Edema

Diabetic Retinopathy Screening in Hong Kong. Dr. Rita Gangwani M.S, FRCS (Ophth), FCOphth(HK), FHKAM Eye Institute, The University of Hong Kong

Tuberous sclerosis presenting as atypical aggressive retinal astrocytoma with proliferative retinopathy and vitreous haemorrhage

The Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care

Accidental foveal burn following pan retinal photocoagulation and its long-term outcome

Diabetic retinopathy (DR) is the leading PROCEEDINGS EVIDENCE-BASED DATA IN THE TREATMENT OF DIABETIC RETINOPATHY*

Prevalence and causes of macular edema and its correlation: an observational study

Transcription:

The Professional Medical Journal DOI: 10.17957/TPMJ/16.2856 ORIGINAL PROF-2856 VISUAL OUTCOME IN DIABETIC MACULAR EDEMA AFTER GRID LASER TREATMENT 1. MBBS.FCPS Assistant Professor Ophthalmology Independent Medical College, 2. MBBS.MCPS.FCPS Associate Professor Ophthalmology Independent Medical College 3. MBBS. Medical Officer THQ Samundari 4. Medical Student Independent Medical College, Correspondence Address: Dr. Faheem Ahmad Associate Professor Ophthalmology Independent Medical College doctorfaheem2000@yahoo.com P-79 Officer Block, Muslim Town, doctorfaheem2000@yahoo.com Article received on: 17/11/2015 Accepted for publication: 24/02/2016 Received after proof reading: 12/04/2016 Dr. Muhmmad Jameel Shahid 1, Dr. Faheem Ahmad 2, DR. Muhammad Asif 3, Muhmmad Nabeel Sultan 4 ABSTRACT: Regarding the causes of blindness, Diabetic retinopathy is a one the major cause of blindness in all types persons from both industrialized and developing countries. Due to inadequate eating habits, prevalence of diabetic retinopathy is increasing. Both focal and diffuse leakage from retinal capillaries can cause Diabetic macular edema. Various treatment modalities for macular photocoagulation are focal laser, Grid laser and modified grid used in patients having diabetic macular edema Study Design: Prospective, interventional, noncompetitive case series. Setting: Department of Ophthalmology, Allied Hospital and Department of Ophthalmology, Divisional Headquarter Hospital. Period: One year from April 2012 to April 2013. Materials and Methods: A total of 200 eyes of 200 patients with clinical significant macular edema that met the inclusion criteria were enrolled. Results: In this study, 200 patients with diabetic macular edema were studied. Of these 121 (60.5%) were males and 79 (39.5%) females with mean age of 38.52 years (SD 7.512, Range 25-50 years). All patients had diffuse, clinically significant macular edema at baseline for which they had received grid laser photocoagulation. Discussion: In recent past number of diabetic patients all over the world has increased that has caused increase incident of diabetic retinopathy.so in patients having diabetic retinopathy, macular edema can cause deterioration in visual acuity during any stage of diabetic retinopathy. The pathogenesis of Diabetic macular edema (DME) is the disruption of inner blood retinal barrier that is known to be associated with metabolic alteration affecting the retinal pigment epithelium or retinal vascular endothelium. Focal and/or grid laser photocoagulation is being considered as the treatment of DME. Conclusion: Macular photocoagulation was found to be an effective method of treatment for CSME among diabetic patients, which has resulted in a positive visual outcome in 87% of the patients (stable and improved vision). Key words: Clinical Significant Macular Edema (Csme), Grid Laser Photo Coagulation INTRODUCTION Regarding the causes of blindness, retinal complication of diabetes are one of the commonest causes leading to blindness in all types persons all over the world. Due to inadequate eating habits, prevalence of diabetic retinopathy is increasing. 1 All patients who are diagnosed as case diabetes mellitus are at risk of developing Diabetic macular edema that cause severe visual loss in any stage of diabetic retinopathy. In diabetic macular edema patient develop painless loss of central vision and vision loss may range from mild vision loss to severe vision loss. 2 Regarding mechanism of visual loss in diabetic retinopathy Diabetic macular edema (DME) is the most common Article Citation: Shahid MJ, Ahmad F, Asif M, Sultan MN. Visual outcome in diabetic macular edema after grid laser treatment. Professional Med J 2016;23(4):478-483. DOI: 10.17957/TPMJ/16.2856 cause of loss of vision in patients suffering from diabetes that can produced in any stage during the course of disease (diabetic retinopathy). 3,4 Both focal and diffuse leakage from retinal capillaries can cause Diabetic macular edema. Early treatment diabetic retinopathy study (ETDRS) group had recommended Macular photocoagulation treatment in diabetic patients having clinically significant macular edema (CSME). 5 Various treatment modalities for macular photocoagulation are focal laser, Grid laser and modified grid used in patients having diabetic macular edema. In focal LASER treatment, Laser 478

2 is applied directly on micro aneurysm causing macular edema while in grid Laser treatment, Laser is applied in GRID pattern around the area of diffuse capillary leakage. For patients who have focal and diffuse leakage on Fundus Flourociene Angiography (FFA) then modified grid that is a combination of focal and grid treatments is applied. 6,7 In case of clinical significant macular edema grid pattern laser is used for areas of diffuse thickening located more than 500 micron from the center of macula and 500 micron from temporal margin of optic disc. Spot size should be 100 to 200 micron, duration of laser 0.10 second. Burns should be gentle and light in intensity which only cause blanching and one burn width apart. Regarding the mechanism by which LASER works in diabetic macular edema is still not explored. However it is considered that the laser is absorbed through melanin pigments present in the epithelium of retina and choroid and in the micro aneurysm by hemoglobin. All these factors lead to increase in oxygen permeability from choroid to inner retina, subsequently hampering the process of neovascularization of retina. Similarly, thrombosis of the micro aneurysm of retinal vessels also decreases the vascular leakage. 9 After laser treatment patient notices the benefit after 3-4 months because initially there is decrease in visual acuity before the treatment becomes effective. In patients having persistent macular edema after macular photocoagulation then in such cases a Additional treatment can be required. Our objective in this article was to study the impact of Grid laser (Argon LASER) treatment on diabetic patients with CSME, in terms of effect on visual acuity. OBJECTIVE To determine the frequency of improvement in the visual acuity and its stability in patients undergoing Laser photocoagulation for diabetic macular edema (GRID PATTERN). MATERIALS AND METHODS This was an interventional, noncompetitive case series carried out at the Department of Ophthalmology, Allied Hospital and Department of Ophthalmology, Divisional Headquarter Hospital. The study was carried out over a period of one year from April 2012 to April 2013. A total of 200 eyes of 200 patients with clinical significant macular edema that met the inclusion criteria were enrolled. We included diabetic patients of all ages and both sexes having non-proliferative diabetic retinopathy with diffuse, clinically significant diabetic macular edema. In these patients, who were selected for our study received Grid laser treatment by Argon Laser in Allied Hospital,. The Green laser photocoagulation is also treatment modality for Clinical significant macular edema in diabetic retinopathy as it is relatively safe and an outdoor procedure. All these patients had clinical significant macular edema due to diabetic retinopathy in any stage of diabetic retinopathy. Before to start this study permission was granted from the institutional Ethical Committee. In all the patients complete History was taken from the patients. After that complete ocular examination done in which anterior segment examination done by slit lamp and posterior segment examination by slit lamp bio microscopy using Volk +90 D or Goldman,s mirror contact lens. Best corrected visual acuity (BCVA) using Snellen.s visual acuity chart was recorded before every session of laser photocoagulation and on each follow-up. Fundus fluorescein angiography was done in patients having decrease in visual acuity in the absence of obvious pathology to rule ischemic maculopathy. Indication for treatment was CSME, i.e CSME exists if Any retinal thickening within 500 micron of the foveal center or Hard exudates within 500 µm of the foveal center that are associated with adjacent retinal thickening or An area of retinal thickening at least 1 disc area in size, any part of which is located within 1 disc area of the foveal center. Treatment of all cases of CSME were done according to recommendations of ETDRS study group. Consent was taken from all patients on prescribed written form. Before to Treatment topical anesthesia eye drops was used in patient eyes. Argon laser machine having green light was 479

3 used to apply Laser. Follow-up examination was done initially on monthly basis followed by 03 monthly visits and subsequently depending on the resolution of macular edema. During the last follow-up BCVA after laser was measured using Snellen,s VA chart. Improvement in vision on the snellen, VA chart by one line or no change in visual acuity was recorded as a positive visual outcome while decrease vision of more than two lines of Snellen,s VA chart was recorded as negative visual outcome. Complete ocular examination were carried out at each follow-up visit. For statistical analysis software SPSS-19 was used and Chi-square test was applied. P value of 0.05 was considered significant. RESULTS In this study, 200 patients with diabetic macular edema were studied. Of these 121 (60.5%) were males and 79 (39.5%) females with mean age of 38.52 years (SD 7.512, Range 25-50 years).all patients had diffuse, clinically significant macular edema at baseline for which they had received grid laser photocoagulation. All the patients were observed for four months. Patient selected for the study were divided into three groups after photocoagulation. Rate of changes in visual acuity was evaluated between three groups. Group A (improvement in visual acuity) This group included those cases with visual acuity improved after Grid laser photocoagulation. 22 eyes of patients (male 72.7%, female 27.3%) out of 200 eyes having improvement after Grid laser photocoagulation. Group B (stable visual acuity) The patients in this group were included those having stable visual acuity after Grid laser photocoagulation. 152 eyes of patients (male 57.9%, female 42.1%) out of 200 eyes having stable visual acuity after laser. Group C (decrease visual acuity) All the patients who have decrease in visual acuity after application of laser in CSME. 26 eyes of patients (male 65.4%, female 34.6%) out of 200 eyes having decreased in visual acuity after application of laser. Frequency Percent Valid Percent Cumulative Percent Male 121 60.5 60.5 60.5 Female 79 39.5 39.5 100.0 Total 200 100.0 100.0 Table-II. Sex wise Distribution of Patients Frequency Percent Valid Percent Cumulative Percent Valid <30 71 35.5 35.5 35.5 36-45 85 42.5 42.5 78.0 46> 44 22.0 22.0 100.0 Total 200 100.0 100.0 Table-III. Age wise Distribution of Patients Frequency Percent Valid Percent Cumulative Percent Valid Improved 22 11.0 11.0 11.0 Stable 152 76.0 76.0 87.0 Decreased 26 13.0 13.0 100.0 Total 200 100.0 100.0 Table-IV. Visual Outcome 480

4 N Mean Std. Deviation 95% Confidence Interval for Mean Lower Bound Upper Bound Improved 22 32.59 6.609 29.66 35.52 Stable 152 39.09 7.308 37.91 40.26 Decreased 26 40.19 7.359 37.22 43.16 Total 200 38.52 7.512 37.47 39.56 Table-V. Descriptive Outcome Figure-1. Distribution of respondents according to improvement of visual aquity Figure-2. Improvement in visual aquity regarding gender. M: F ratio: Age group: (Table III) Follow up (Outcome): Improved visual acuity (group A): Stable visual acuity (group B): Decrease visual acuity (group C): Outcome M : F ratio: Age group (Outcome): Actual result: Table-I. 60.5% : 39.5% (Table II) Range 25-50 years 03 Months 11% (table IV) 76 % (table IV) 13 % (table IV) 60.5% : 39.5% 35.5%, 42.5%, 22% (Table V) the treatment of CSME. Grid laser treatment for CSME is believed to reduce permeability of leaky blood retinal barrier but several reports indicate that photocoagulation itself may induce blood retinal barrier. In patients with CSME laser treatment is applied to prevent further loss of vision. Because Laser treatment usually does not improve vision once it has decreased due macular edema. 10 DISCUSSION In recent past number of diabetic patients all over the world has increased that has caused increase incident of diabetic retinopathy. So in patients having diabetic retinopathy, macular edema can cause deterioration in visual acuity during any stage of diabetic retinopathy. The pathogenesis of Diabetic macular edema (DME) is the disruption of inner blood retinal barrier that is known to be associated with metabolic alteration affecting the retinal pigment epithelium or retinal vascular endothelium. Focal and/or grid laser photocoagulation is being considered as The recommendation regarding timing of laser treatment is that it should be performed prior to occurrence of visual loss because the risk of visual loss due to macular edema justifies the adverse effect of laser treatment. Numerous studies reveal that treatment of macular edema at early stage before significant loss of vision has better outcome. Photocoagulation studies in CSME such as Olk et al. and the study conducted at multiple centres of UK has shown that laser photocoagulation of maculae has positive outcome in treating macular edema and keeping the vision stable. 11,12 481

5 In our study, Grid laser photocoagulation was performed on all patients who developed clinical significant macular edema in diabetic retinopathy. These includes 200 eyes of diabetic patients with clinical significant macular edema between 25 to 50 years of age. Patients are followed up after 3 months post laser treatment and visual acuity noted and results were 11% improved in visual acuity, 76% having stable in visual acuity and 13% deteriorates in vision. Lee CM, and Olk RJ have records of 302 eyes of 185 patients with diffuse diabetic macular edema with or without cystoid macular edema. Between the years 1981 and 1990 Lee CM, and Olk RJ treated all such cases with modified grid laser photocoagulation. 13 The result of their study was visual acuity improved in 14.5%, unchanged in 60.9%, and worse in 24.6% after modified Grid Laser treatment. These results showed that in eyes with diffuse diabetic macular edema for assessing long-term visual outcome, modified grid laser photocoagulation is good treatment in maintaining or improving visual acuity. The study conducted by United Kingdom Prospective Diabetes Study (UKPDS) showed that the 40.5% patients noticed decrease in VA and only 3% had significant visual loss even after receiving in spite of laser treatment. Some studies also reported the adverse effects of laser photocoagulation that include scotomas, field constriction, decrease in dark adaptation, development of choroidal neovascularization and persistence of macular edema. So when laser is deemed necessary, the patient should be informed of the risks and benefits of the procedures. As an adjunct to laser coagulation some latest modes of treatment for diabetic macular edema consist of intraocular steroids, antivascular endothelial growth factor and protein kinase c-beta inhibition. A study conducted by Michael SI et al compared long-term visual outcome, following intravitreal steroids and photocoagulation, they showed superiority of photocoagulation over the intravitreal steroids. 14 The guidelines of ETDRS for laser photocoagulation are to use it as first line treatment. Also, good control of other risk metabolic factors like hypertension and hyperlipidemia etc should be the main stay of treatment along with laser at any phase of the disease. A limitation of the present investigation is the short follow-up, due to which the long-term safety and efficacy of the treatment could not be assessed. The limitation of the study is due to lack of important investigation that was optical coherence tomography (OCT). Because OCT helpful in monitoring and quantifying macular edema. CONCLUSION Macular photocoagulation was found to be an effective method of treatment for CSME among diabetic patients, which has resulted in a positive visual outcome in 87% of the patients (stable and improved vision). Effective control of diabetes, duration of diabetes, and timely treatment are the factors which influence the post-laser visual outcome. Copyright 24 Feb, 2016. REFERENCES 1. Guan K, Hudson C, Wong T, Kisilevsky M, Nrusimhadevara RK, Lam WC, et al. Retinal hemodynamic in early macular edema. Diabetes 2006; 55:813-8. 2. Meyer CH. Current treatment approaches in diabetic macular edema. Ophthalmologica 2007; 221:118-31. 3. Deborah Pavan Langston Manual of Ocular diagnosis and therapy - 4 th ed. Little Brown and Company; 1996. p. 162-5 4. Yanof M, Duker JS. Diabetic Retinopathy, Ophthalmology, 2nd ed, Mosby; 2004. p. 877-85. 5. Early Treatment Diabetic Retinopathy study Research group. Early Photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology 1991; 98:766-85. 6. Bloom SM, Brucker AJ. Laser surgery of the posterior segment, 2nd ed, Lippincott Williams and Wilkins; 1997. p. 78-99. 7. Early Treatment Diabetic Retinopathy Research group. Photocoagulation for diabetic macular edema: 482

6 ETDRS report No 1. Arch Ophthalmol 1985; 103:1796-806. 8. Dorner M, Pinget M,Brogard JM. Essential labile diabetes. MMW Munch Med Wochenschr 2009; 119: 671 4. 9. Henkind P, Hansen RI, Szalay J. Ocular circulation. Physiology of the human eye and visual system. Harper & Row 1979; 98-155. 10. Bloom SM, Brucker AJ. Laser surgery of the posterior segment, 2nd ed, Lippincott Williams and Wilkins; 1997. p. 78-99. 8. 11. Olk RJ. Modifi ed grid argon laser photocoagulation for diffuse diabetic macular edema. Ophthalmology 1986; 93:938-50. 12. The British multicenter study. Townsend C, Bailey J, Kohner E. Xenon arc Photocoagulation for the treatment of diabetic maculopathy: Interim report of a multicentre controlled clinical study. Br J Ophthalmol 1980; 64:385-91. 13. Lee CM, Olk RJ. Modifi ed grid laser photocoagulation for diffuse diabetic macular edema, long term visual results. Ophthalmology 1991; 98: 1594-602. 14. Michael SI, Allisson R Edwards, Roy W Beck, Neil M Bressler. A randomized trial comparing intravitreal triamcinolone acetonide and focal / grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115: AUTHORSHIP AND CONTRIBUTION DECLARATION Sr. # Author-s Full Name Contribution to the paper Author=s Signature 1 Dr. Muhmmad Jameel Shahid Concept & data collection 2 3 4 Dr. Faheem Ahmad Dr. Muhammad Asif Muhmmad Nabeel Sultan Concept & design, Critical expertise & writing, final approval Concept & data collection Help in data collection 483